BrainsWay’s Groundbreaking Approval for Young Patients
BrainsWay Ltd. is making significant strides in the realm of mental health treatment with its recent approval from the U.S. Food and Drug Administration (FDA). This approval expands the reach of the Deep Transcranial Magnetic Stimulation (Deep TMS™) system, allowing it to serve adolescents aged 15 to 21 who are grappling with major depressive disorder (MDD).
Changed Landscape for Adolescent Mental Health
“This FDA clearance marks a vital moment for the adolescent community,” said Dr. Colleen Hanlon, VP of Medical Affairs at BrainsWay. “Many young individuals often find themselves underserved, reliant on traditional medications that may not provide the relief they need. With Deep TMS™, we can bring a new level of hope and effectiveness into their treatment options.”
The Research Behind the Clearance
The FDA’s green light followed an extensive submission by BrainsWay, which included one of the largest databases of real-world patient information relating to adolescent neuromodulation. This dataset encompassed results from over 1,120 adolescents across various TMS centers in the United States, highlighting the therapy’s effectiveness through rigorous analysis. After 36 sessions of treatment, adolescents reported an average improvement in their depressive symptoms, showcasing a response rate of over 66%.
Comprehensive Improvement Beyond Depression
Not only did patients experience significant reductions in depression scores, but many also reported decreased anxiety levels. This dual benefit is a promising sign for both clinicians and families seeking holistic treatment solutions for young patients. The deep TMS protocols specifically utilized high-frequency stimulation, demonstrating their efficacy through rigorous clinical data, reinforcing the treatment’s safety as well.
Impact on Families and Patient Outcomes
Hadar Levy, CEO of BrainsWay, emphasized the emotional weight this therapy can lift from adolescent patients and their families. “For years, many families have struggled with finding effective treatments for their children’s mental health issues,” he stated. “Now, we are positioned to change that narrative significantly. Approximately 5 million adolescents face MDD each year in the United States alone; being able to provide solutions for this population is a monumental achievement.”
A Unified Approach to Treatment
With this expanded indication, the BrainsWay Deep TMS™ system is now the only treatment that accommodates the needs of both adults and adolescents suffering from MDD while utilizing the same stimulation methodologies. This allows for continuity in care that both patients and providers will appreciate, simplifying treatment planning.
The Broader Context of MDD
MDD represents a leading global health concern, contributing heavily to disability worldwide. It particularly affects those who have struggled with traditional therapies that have failed to yield satisfactory results. The implications of this are profound—extended suffering and increased healthcare costs burden these patients, often leading them to riskier outcomes like substance abuse or suicidal behavior.
About BrainsWay
Founded in 2003, BrainsWay has become a trailblazer in advanced noninvasive neurostimulation treatments designed for various mental health disorders. Its innovative Deep TMS™ platform reflects the company's commitment to advancing neuroscience with transformative potential for patients. BrainsWay holds three FDA-cleared indications and continues to engage in clinical trials, expanding its influence in the psychiatric and neurological fields.
Frequently Asked Questions
What is Deep TMS™ and how does it work?
Deep TMS™ is an advanced neuromodulation therapy that uses magnetic fields to stimulate nerve cells in the brain. It's designed to treat major depressive disorder and can reduce comorbid anxiety symptoms.
What age group is now eligible for Deep TMS™ treatment?
Deep TMS™ is now approved for use in adolescents aged 15 to 21, expanding treatment options for this underserved group.
What kind of results have been observed in clinical studies?
Clinical studies have shown an average improvement of 12.1 points on depression scales, with a response rate of over 66% in adolescents after 36 treatment sessions.
How does this approval impact the treatment landscape?
This approval enables broader access to effective treatment for many adolescents struggling with mental health issues, providing a noninvasive alternative to traditional pharmacological therapies.
Is BrainsWay involved in further research?
Yes, BrainsWay continues to conduct clinical trials for Deep TMS in various psychiatric and neurological disorders, consistently aiming to improve healthcare access and outcomes for patients.
